https://clinicaltrials.gov/ct2/show/NCT02804763?type=Intr&cond=Lupus&phase=012345&lupd_s=01%2F15%2F2019&lupd_d=14
Condition : Systemic Lupus Erythematosus (SLE)
Interventions : Drug: Placebo; Drug: Dapirolizumab pegol (DZP)
Sponsor : UCB Biopharma S.P.R.L.
Completed
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
NCT02804763
Fri, 17 Jun 2016 12:00:00 EDT
>>> Updated January 29, 2019 >>> study status changed from active, not recruiting to completed
